

Pharmacy Services

(800) 522-0114, option 4

September 1, 2017

RE: Prior Authorization of Medications Used to Treat Lung Cancer – Effective October 1, 2017

Dear Provider,

Effective October 1, 2017, the Oklahoma Health Care Authority (OHCA) will require a prior authorization (PA) for the following medications: Xalkori® (Crizotinib), Zykadia® (Ceritinib), Alecensa® (Alectinib), Alunbrig™ (Brigatinib), Tarceva® (Erlotinib), Gilotrif® (Afatinib), Tagrisso™ (Osimertinib), Cyramza® (Ramucirumab), and Tecentriq® (Atezolizumab).

If a SoonerCare member is currently on therapy with one of these medications, the medication will be “grandfathered”. If the drug is obtained through the pharmacy claim system, it will be automatically prior authorized based on past claims. Medical claims typically lag behind the treatment date, and we may be unable to see current therapy. In order to avoid a disruption in therapy we recommend submitting a PA for those members who started on therapy after 07/01/2017. Dates of previous doses must be listed on the PA form in order for our staff to know the patient has already received therapy.

The specific PA requirements for each drug are located on the SoonerCare website at www.okhca.org/pa in the “Oncologic” therapeutic category. A drug-specific prior authorization form is required, which can be found on the website at OHCA Forms. Look for forms labeled PHARM-75 through PHARM-83.

All medication PA requests are submitted to the Pharmacy Prior Authorization Unit at the fax number located at the bottom of the form. Do not submit the request to Medical Authorization Unit or via the provider portal.

If you have questions, please contact the pharmacy authorization unit at (800) 522-0114, option 4.

Thank you for your continued service to Oklahoma’s SoonerCare members.